TSX-V: GENX
Subscribe


  1. Home
  2. /
  3. Investors

The Opportunity

The Ophthalmic drug industry grosses over $1.8 billion Canadian annually and is the fastest growing segment of the Canadian pharmaceutical industry. Genix’s plan in the future is to research ocular herbal products and acquire an additional 70-100 ophthalmic drug products over the next 3 years.

Positioned For Growth

  • Increasing incidence of eye diseases among all ages.
  • Ophthalmic drugs patent cliff of $3B in next five years providing a significant growth opportunity for generic versions.
  • Canadian ophthalmic segment has a 32.6% annual growth rate.
  • Acquiring additional 70-100 ophthalmic drug products over the next 3 years.

Competitive Advantage

  • Global market opportunity for generic ophthalmics exports
  • Only four drug companies controlling the Canadian ophthalmics market
  • Canadian ophthalmic drugs among the highest priced in the world
  • Ophthalmic drugs have accelerated registration approvals as they do not require BA/BE studies to be done

Market Overview

GENX Chart by TradingView

GENX Fundamental Data by TradingView

GENX Symbol Info by TradingView

 

 

 

 

 

TSX-V: GENX

Corporate Deck
(currently being updated)

Financials

Recent Media

Share Structure

59,359,131

Issued & Outstanding

65,112,776

Fully diluted common shares

5,753,645

Warrants & Options

For detailed financials, please visit SEDAR

Research and Development and Future Outlook

  • Developing novel products for topical treatment of Age Related Macular Degeneration (ARMD) and eye strain, as well as various products for eye related diseases
  • Continuing to build a pipeline of generic prescription drugs as Genix anticipates to increase the portfolio size from 30 generics to an additional 40 to 50 dossiers

Corporate Governance And Compensation Committee Charter

View

Stay In Touch

Trade Alert – Delivering the latest product trends and industry news straight to your inbox.

Subscribe


Menu